RESI Europe 2025
Redefining Early Stage Investments (RESI), which is held in the United States, will return to Europe for the second consecutive year, and Barcelona has been selected as the host city for its second edition with the support of Biocat, in collaboration with the Government of Catalonia and the City of Barcelona. The event will take place from April 1 to 3, 2025, combining an in-person day at the InterContinental Barcelona Hotel and two virtual days. The event will be a key meeting point for startups and scaleups in the life sciences and health sector.

01.04.2025
03.04.2025
Hotel InterContinental Barcelona
Life Science Nation (LSN) and Biocat
Biocat, Generalitat de Catalunya and Ajuntament de Barcelona
The international conference Redefining Early Stage Investments (RESI), organized by Life Science Nation (LSN), will take place in Barcelona from April 1 to 3, 2025, with the goal of connecting early-stage startups with international investors to establish strategic alliances. Additionally, it will also be aimed at scaleups, service providers, and tech hubs. This boutique conference, typically held in the United States, will return to Europe and choose Barcelona to host its second edition thanks to the collaboration of Biocat, the City of Barcelona, and the Government of Catalonia.
The event will bring together over 250 investors specializing in seed, Series A, and Series B stages, and will focus on sectors such as drug development, medical devices, diagnostics, and digital health. The first day of the conference will be held in person and will include partnering sessions and activities like the Healthtech Market Access Panel, organized by Biocat. The following two days will be held virtually, with spaces for pitches, workshops, and keynote conferences in the sector.
A unique and different conference in Europe
- It is the only event with a 1:1 ratio of investors to startups. RESI EUROPE Barcelona will bring between 250 and 300 international investors. These investors are part of an international network and are looking for seed, Series A, and Series B opportunities.
- It is an event dedicated to global investors and licensing partners in the pharmaceutical, medical devices, diagnostics, and digital health sectors.
- Roundtables and workshops: learn about the latest market trends, investment strategies, and best business practices.
- The Innovators Pitch Challenge (IPC) guarantees that a startup can present itself to a panel of investors that align with its development stage and product. Each participant will receive written feedback from the investor.
- Networking: RESI is not only a platform for exchanging investment opportunities but also a space for collaboration and innovation. Create new synergies and strategic alliances with other stakeholders through the partnering platform.
- Sponsorship package: multiple benefits to increase visibility and connections during the conference.
Discounts for entities of the BioRegion
The alliance to bring the international conference Redefining Early Stage Investments (RESI) to Barcelona in 2025 will offer, once again, exclusive benefits for organizations in the BioRegion of Catalonia.
BioRegion companies & organizations | 3 Days | 2 Days | Acces Pass |
Dicount codes | BIOCAT3DAY | BIOCAT2DAY | BIOCATAAP |
Earlybird Until February 28th | 895 € | 395 € | 300 € |
Standard | 995 € | 545 € | 445 € |
Preparation Webinar Series (open to the public)
- Feb 12, 2025 12PM CET: Introduction to RESI Europe – Sign up
- Feb 18, 2025 11:00 AM ET: Tips on Pitching – Sign up
- Mar 6, 2025 11:00 AM ET: The LSN Event Partnering Process – Sign up
- Mar 20, 2025 11:00 AM ET: RESI Europe Partnering Tutorial – Sign up
Complimentary Educational Program included for the 15 IPC selected companies
Global Fundraising Campaign Bootcamp:
The 15 selected companies will have exclusive access to a 5-day intensive course on global fundraising, valued at €2,000, to increase their chances of success in closing funding rounds.
Virtual Class:
- Feb 24th 5PM CET: Nuts and bolts of preparing and executing a global partnering campaign and road show.
- Feb 27th 5PM CET : Tagline and elevator pitch.
- Mar 3rd 5PM CET: Breakout session 1.
- Mar 6th 5PM CET: Executive summary, one page data sheet, pitch deck.
- Mar 10th 5PM CET : Breakout session 2.
- Mar 13th 5PM CET: Maximizing your pitch, poster preparation and navigating the partnering system, using a CRM.
March 31 : Half-day education course 9AM-1PM
This intensive bootcamp, delivered by Life Science Nation, will provide you with essential tools to connect with top investors in the sector and secure the necessary funding.
Advantages of participating in the IPC
- Opportunity to pitch in front of a panel of pre-selected investor judges and expert investors.
- 6 minutes of presentation and 7 minutes of questions and answers.
- Session moderators will strictly enforce these time limits to ensure a fair and equitable opportunity for all participants.
- Participants will be assigned to a live presentation session and Q&A based on their sector or technology.
IPC Prizes
All registered attendees at RESI will receive 5 "RESI Cash" vouchers when they register for the conference. All attendees will be able to use "RESI Cash" to "invest" in the IPC finalist companies they find most attractive. The 3 companies with the most "RESI Cash" invested will be announced during the IPC awards ceremony and will receive the following:
- 1st place (valued at €12,000): Free entry to 3 RESI events* of their choice (up to 2 entries per event).
- 2nd place (valued at €8,000): Free entry to 2 RESI events* of their choice (up to 2 entries per event).
- 3rd place (valued at €4,000): Free entry to 1 RESI event* of their choice (up to 2 entries per event).
*Free entries must be redeemed within one calendar year after finishing in the top three.
*For more information, contact Adrià Gómez (agomez@biocat.cat)
Sessions of interest
Round Table
Healthtech Market Access Panel Discussion
To explore the challenges and strategies in achieving market access for healthtech innovations, focusing on regulatory hurdles, coverage, coding, reimbursement and adoption pathways, and the role of data and digital tools in healthcare.
01/04/2025
11:00 AM - 11:50 AM
Hotel InterContinental Barcelona
Organized by Biocat
Moderator:
- Carmen Ríos, CEO Doctomatic
Speakers:
- Ramon Maspons, Chief Health Innovation Strategist. Ministry of Health, Government of Catalonia.
- Meike Bomhof, VP Market Access of Avania.
- Ana Maiques, CEO Neuroelectrics.
- Francisco Rodríguez, Medical Device Manager and Lead Auditor of Asphalion.
Institutional Reception and IPC Award Ceremony
01/04/2025
5 PM -7 PM
Hotel InterContinental Barcelona (Terrace Garden)
5 PM Welcome from Dennis Ford, Founder and CEO of LSN
5:10 PM Speech by Xavier Mayo, Head of the Barcelona Investment Office – BIO, Barcelona City Council
5:20 PM Presentation of the Innovator’s Pitch Challenge Awards by Dennis Ford, Xavier Mayo and Robert Fabregat (General Director of Biocat)
6 PM Cocktail Networking.
List of investors
Inversor | Country | Continent |
Global Emerging Markets (GEM) | United States | America |
Technomark Life Sciences | United States | America |
Pharma Capital Partners | United States | America |
AZCA, Inc | United States | America |
Plug and Play Ventures | United States | America |
Shimadzu Corporation | Japan | Asia |
Asymmetry Ventures | United States | America |
Northlea Partners | United States | America |
Mid Atlantic Bio Angels | United States | America |
Aphelion Capital, LLC | United States | America |
Life Science Angels | United States | America |
Myeloma Investment Fund | United States | America |
Evidence Ventures | United States | America |
Taiho Ventures | United States | America |
LongGame | United States | America |
Transatlantic Life Science Venture | United States | America |
Novartis | United States | America |
FoxHill Asset Management | United States | America |
Atlas Capital Ventures, LLC | United States | America |
NYBC Ventures | United States | America |
Evio Venture Capital | United States | America |
Meritage Technologies Inc. | United States | America |
Curie.Bio | United States | America |
BioMap Inc. | United States | America |
Coho Deeptech | United States | America |
Gaingels | United States | America |
Angel Investor | United States | America |
Thielsen Capital | United States | America |
Accequa AB | United States | America |
PROMERCA Family Office | United States | America |
InVivium Capital | United States | America |
Pappas Capital | United States | America |
MEDA Ventures | United States | America |
Springhood Ventures | United States | America |
1004 Venture Partners | United States | America |
Oncology Ventures | United States | America |
Individual Angel | United States | America |
NVIDIA Corporation | United States | America |
Ajinomoto Corporate Venture Capital | United States | America |
Fast Track Initiative | Japan | Asia |
General Inception | United States | America |
Mass Medical Angels | United States | America |
Rising Pharmaceuticals | United States | America |
Aditum Bio | United States | America |
BOLD Longevity Growth Fund | United States | America |
Voloridge Health | United States | America |
TransAtlantic Angel Conference | United States | America |
Kicker Ventures | United States | America |
Global Emerging Markets (GEM) | United States | America |
Voloridge Health | United States | America |
Meiji Pharma USA | United States | America |
CPI Enterprises | United Kingdom | Europe |
RYSE | United Kingdom | Europe |
Global Bio Fund (Jaya Ventures) | United Kingdom | Europe |
Kerna Ventures | United Kingdom | Europe |
Manta Ray Ventures | United Kingdom | Europe |
GGS Associates | United Kingdom | Europe |
NG Bio | United Kingdom | Europe |
Claret Capital Partners | United Kingdom | Europe |
Deep Science Ventures | United Kingdom | Europe |
O2h Ventures | United Kingdom | Europe |
IPF Partners | Switzerland | Europe |
Endeavor Venture Fund & Venture Studio | Switzerland | Europe |
Breslin AG | Switzerland | Europe |
Redalpine | Switzerland | Europe |
Debiopharm International S.A. | Switzerland | Europe |
Convergence Partners AG | Switzerland | Europe |
Ferring Pharmaceuticals | Switzerland | Europe |
Aliath Bioventures | Spain | Europe |
Capital Cell | Spain | Europe |
Ysios Capital | Spain | Europe |
Clave Capital | Spain | Europe |
Inveready Asset Management | Spain | Europe |
Invivo Partners | Spain | Europe |
Plutus Advisors LLC | Spain | Europe |
We Venture Capital | Spain | Europe |
Namarel Ventures | Spain | Europe |
BeAble Capital | Spain | Europe |
LifeLink Ventures | Spain | Europe |
Grifols | Spain | Europe |
Ship2B Ventures | Spain | Europe |
Montana Impact Fund | Spain | Europe |
Nara Capital | Spain | Europe |
Inveniam Group | Spain | Europe |
Columbus Venture Partners | Spain | Europe |
Inveniam Group | Spain | Europe |
Montana Impact Fund | Spain | Europe |
CRB Inverbio | Spain | Europe |
Inveready Asset Management | Spain | Europe |
Ship2B Ventures | Spain | Europe |
Criteria Bio Ventures | Spain | Europe |
Inveready Asset Management | Spain | Europe |
Bio & Tech Smart Capital - Noso Capital | Spain | Europe |
Montana Impact Fund | Spain | Europe |
University of Navarra (Universidad de Navarra) | Spain | Europe |
Verge Health Tech Fund | Singapore | Asia |
LAFANA | Saudi Arabia | Asia |
CS Ventures | New Zealand | Oceania |
dsm-firmenich Ventures | Netherlands | Europe |
Lumo Labs | Netherlands | Europe |
M Ventures | Netherlands | Europe |
Brightlands Venture Partners | Netherlands | Europe |
Swanbridge Capital | Netherlands | Europe |
Caju Venture Partners | Netherlands | Europe |
EQT Life Sciences | Netherlands | Europe |
Brightlands Venture Partners | Netherlands | Europe |
NLC Health Ventures | Netherlands | Europe |
Ikigai Ventures | Luxembourg | Europe |
LongeVC | Latvia | Europa |
Celltrion | Republic of Korea | Asia |
Asahi Intecc USA Inc | Japan | Asia |
Maruho Co., Ltd. | Japan | Asia |
EA Pharma Co., Ltd. | Japan | Asia |
Santen | Japan | Asia |
Asahi Kasei Pharma Corporation | Japan | Asia |
Sumitomo Pharma Co., Ltd. | Japan | Asia |
FUJIFILM Corporation | Japan | Asia |
JT Pharma | Japan | Asia |
Medical Incubator Japan (MIJ) | Japan | Asia |
Panakes Partners | Italy | Europe |
Angelini Ventures | Italy | Europe |
Digital Networks PLC | Italy | Europe |
Novaterra | Italy | Europe |
Chiesi | Italy | Europe |
Women Angels for Steam | Italy | Europe |
XGEN Venture | Italy | Europe |
AurorA Science | Italy | Europe |
Corundum Neuroscience | Israel | Asia |
Arkin Bio | Israel | Asia |
Seroba Life Sciences | Ireland | Europe |
Kernel Capital | Ireland | Europe |
BioIdeations | India | Asia |
FastVentures | Hungary | Europe |
Summer Atlantic Capital | China | Asia |
Apollo Health Ventures | Germany | Europe |
ekwithree | Germany | Europe |
RV Invest GmbH | Germany | Europe |
Peppermint Venture Partners | Germany | Europe |
Neuraxpharm | Germany | Europe |
AdBio Partners | France | Europe |
Sofinnova Partners | France | Europe |
M2Care | France | Europe |
Andera Partners | France | Europe |
Innovestor | Finland | Europe |
Look AI Ventures | Czech Republic | Europe |
Shanda Ventures | China | Asia |
Gaorong Capital | China | Asia |
Autobio Venture Capital | China | Asia |
IHM-GBA | China | Asia |
Launchit Ventures | Canada | America |
Desire Ventures | Canada | America |
Leva Capital | Canada | America |
Quatá Confidence Capital | Brazil | America |
Heran Partners | Belgium | Europe |
TCD Capital | Belgium | Europe |